证券代码：600713 证券简称：南京医药 编号：ls2023-073 南京医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 会议召开时间：2023年9月13日（星期三）上午 10:00-11:30 ● 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.co m/） ● 会议召开方式：上证路演中心网络视频、图文展示及文字互动 ● 投资者可于2023年9月6日（星期三）至9月12日（星期二）16:00前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司邮箱600713@njyy.com进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 南京医药股份有限公司（以下简称"公司"）已于2023年8月31日发布了2023年半 年度报告，为便于广大投资者更全面深入地了解公司2023年半年度的经营成果、财务 状况，公司计划于2023年9月13日上午10:00-11:30举行2023年半年度业绩说明 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥27,343,124,491.26, representing a 14.21% increase compared to ¥23,940,993,596.60 in the same period last year[19]. - The total profit for the period was ¥521,521,181.46, up 13.01% from ¥461,468,360.84 in the previous year[19]. - The net profit attributable to shareholders decreased by 7.38% to ¥308,641,881.41 from ¥333,218,365.52 year-on-year[19]. - The net cash flow from operating activities was negative at -¥2,721,066,361.61, compared to -¥2,390,346,586.26 in the previous year[19]. - Basic earnings per share decreased by 14.13% to ¥0.237 from ¥0.276 in the same period last year[20]. - The weighted average return on net assets fell to 5.007% from 6.149%, a decrease of 1.142 percentage points[20]. - The company's operating revenue increased by 14.21% to CNY 27,343.12 million, while operating costs rose by 14.84% to CNY 25,706.23 million[49]. - The net profit after deducting non-recurring gains and losses for the first half of 2023 was approximately ¥300 million, a decrease of 7.38% compared to the same period last year[140]. - The total comprehensive income for the first half of 2023 was ¥114,066,198.01, down from ¥162,690,412.98 in the same period last year[152]. Assets and Liabilities - The total assets of the company increased by 5.44% to ¥33,371,894,066.38 from ¥31,650,959,639.82 at the end of the previous year[19]. - The total liabilities reached ¥26.43 billion, up from ¥24.96 billion at the end of the previous year[145]. - The company's total equity increased to approximately ¥6.94 billion from ¥6.69 billion at the end of the previous year[145]. - The debt-to-asset ratio was 79.20%, slightly up from 78.85% at the end of the previous year[140]. - The current ratio improved to 1.37, up 4.58% from 1.31 at the end of the previous year[140]. - Short-term borrowings increased significantly to ¥4.30 billion from ¥1.80 billion at the end of the previous year[145]. - The company's total liabilities as of June 30, 2023, were ¥14.60 billion, an increase from ¥12.86 billion at the end of 2022, representing a growth of 13.5%[147]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥2,721,066,361.61, compared to a net outflow of ¥2,390,346,586.26 in the first half of 2022[155]. - Cash and cash equivalents decreased to approximately ¥2.01 billion from ¥2.33 billion at the end of 2022[144]. - The company raised ¥12,326,769,660.05 in borrowings during the first half of 2023, compared to ¥12,557,214,316.64 in the same period of 2022[155]. - The company’s investment activities resulted in a net cash outflow of ¥46,203,076.68 in the first half of 2023, contrasting with a net inflow of ¥1,566,033.68 in the same period of 2022[155]. Business Operations - The company operates 604 retail stores, including 11 regional brand chain institutions[30]. - The company is focusing on digitalization and modern supply chain system construction to enhance operational efficiency[26]. - The company is expanding its business into "Internet+" healthcare services and third-party logistics[27]. - The company aims to strengthen its core competitiveness while adapting to external environmental changes[26]. - The company is exploring multi-modal pharmaceutical retail business and enhancing pharmacy service levels[30]. - The company operates 163 specialized pharmacies, expanding its DTP pharmacy business and enhancing resource collaboration in the prescription market[31]. Research and Development - Research and development expenses increased by 32.68% to CNY 17.90 million, reflecting a commitment to enhancing information technology development[49]. - The company introduced 35 new drug varieties over the past three years, achieving a new drug sales growth of 635.06% with a new drug introduction rate of 86.18%[45]. - The company incurred research and development expenses of ¥5,171,698.11 in the first half of 2023, up from ¥3,732,279.28 in the previous year, reflecting a focus on innovation[152]. Risk Management - There were no significant risk events reported during the period, and the company has outlined potential risks in the management discussion section[6]. - The company is facing risks from prolonged payment terms from public medical institutions, which may affect cash flow efficiency[72]. - The company has established a comprehensive risk management framework to support its operational and strategic objectives[79]. Corporate Governance - The company aims to enhance its governance structure and market-oriented mechanisms as part of its "first-class enterprise" initiative from 2022 to 2025[43]. - A new internal audit management system was established to enhance risk control and internal supervision, approved by the board in early 2023[79]. - The company is focusing on strengthening its internal audit system and has revised its internal audit regulations to ensure compliance and effectiveness[79]. Shareholder Information - The total number of ordinary shareholders reached 58,523 by the end of the reporting period[125]. - The largest shareholder, Nanjing New Industry Investment Group, holds 44.13% of the shares, totaling 578,207,286 shares[127]. - The company completed the repurchase and cancellation of 84,000 restricted shares under the 2021 incentive plan, reducing the total share capital to 1,310,231,012 shares[121]. Financing Activities - The company plans to issue convertible bonds to raise up to CNY 1,081.49 million for digital transformation and logistics projects, enhancing core competitiveness[43]. - Nanjing Pharmaceutical Co., Ltd. issued a total of 500 million yuan in short-term financing bonds with interest rates ranging from 2.27% to 2.77% across different tranches[136]. - The total bond issuance for the year 2023 is projected to reach 4 billion yuan, aimed at supporting operational and expansion activities[136]. Market Position - The company ranks sixth in the domestic pharmaceutical circulation industry in terms of business scale as of 2022[27]. - The total sales of the national pharmaceutical circulation market reached 2,751.6 billion yuan, with a year-on-year growth of 6.0%, a slowdown of 2.5 percentage points[25]. - The retail market sales amounted to 599.0 billion yuan, with a year-on-year growth of 10.7%, accelerating by 3.3 percentage points[26].

南京医药股份有限公司（以下简称"公司"）于 2022 年 4 月 28 日召开公司 2021 年年度股东大会，会议审议通过《关于公司 2022 年注册发行超短期融资券的 议案》，同意公司向中国银行间市场交易商协会（以下简称"交易商协会"）申请 注册发行不超过人民币 60 亿元的超短期融资券。 2022 年 8 月，公司收到交易商协会《接受注册通知书》（中市协注【2022】 SCP301 号），交易商协会决定接受公司超短期融资券注册，注册金额为人民币 60 亿元，注册额度自通知书落款之日（2022 年 8 月 23 日）起 2 年内有效。公司在注 册有效期内可分期发行超短期融资券。 二、公司前期发行的超短期融资券情况： 公司目前已发行但尚未到期兑付的超短期融资券具体情况如下： 证券代码：600713 证券简称：南京医药 编号：ls2023-066 南京医药股份有限公司 2023 年度第十三期超短期融资券发行结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次超短期融资券发行审议情况： 1 期兑付。 2023 年 7 ...

南京医药股份有限公司 2023 年度第十二期超短期融资券发行结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次超短期融资券发行审议情况： 南京医药股份有限公司（以下简称"公司"）于 2022 年 4 月 28 日召开公司 2021 年年度股东大会，会议审议通过《关于公司 2022 年注册发行超短期融资券的 议案》，同意公司向中国银行间市场交易商协会（以下简称"交易商协会"）申请 注册发行不超过人民币 60 亿元的超短期融资券。 2022 年 8 月，公司收到交易商协会《接受注册通知书》（中市协注【2022】 SCP301 号），交易商协会决定接受公司超短期融资券注册，注册金额为人民币 60 亿元，注册额度自通知书落款之日（2022 年 8 月 23 日）起 2 年内有效。公司在注 册有效期内可分期发行超短期融资券。 证券代码：600713 证券简称：南京医药 编号：ls2023-065 二、公司前期发行的超短期融资券情况： 公司目前已发行但尚未到期兑付的超短期融资券具体情况如下： 1 期兑付。 2023 年 7 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 14,081,790,518.45, representing a year-on-year increase of 20.35%[3] - The net profit attributable to shareholders for the same period was CNY 149,157,852.44, reflecting a growth of 12.53% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 149,497,880.77, which is an increase of 24.64% year-on-year[4] - The basic and diluted earnings per share for Q1 2023 were both CNY 0.114, representing a 1.79% increase year-on-year[4] - Net profit for Q1 2023 reached CNY 183.61 million, an increase of 20.93% compared to CNY 151.91 million in Q1 2022[33] - Operating profit for Q1 2023 was CNY 252.13 million, up from CNY 212.66 million in the same period last year, reflecting a growth of 18.59%[33] - The company reported a total comprehensive income of CNY 201.09 million for Q1 2023, compared to CNY 121.04 million in Q1 2022, marking a growth of 66.23%[34] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -3,456,016,751.84, indicating a significant decrease due to increased accounts receivable[4] - As of March 31, 2023, total assets amounted to CNY 32,857,679,992.74, compared to CNY 31,650,959,639.82 at the end of 2022[30] - The company's cash and cash equivalents were CNY 1,387,527,241.52, down from CNY 2,327,195,848.59 at the end of 2022[29] - The company's current liabilities increased to CNY 23,160,572,200.30 as of March 31, 2023, from CNY 22,283,780,193.56 at the end of 2022[30] - The company's inventory increased to CNY 6,186,953,579.93 as of March 31, 2023, compared to CNY 5,787,307,265.45 at the end of 2022, indicating a growth of 6.9%[29] Financing Activities - The company issued a total of CNY 20 billion in short-term financing bonds in 2023, with the first four issuances each totaling CNY 5 billion[9][10] - The company issued a total of RMB 500 million in ultra-short-term financing bonds in both the fifth and sixth phases in 2023[11][12] - The company received a registration notice for medium-term notes with a total amount of RMB 5 billion, valid for two years from February 1, 2023[13] - The company approved a borrowing limit of up to RMB 4 billion from its controlling shareholder for daily operational funding[21] - The company’s subsidiary, Nanjing Medicine Hubei Co., Ltd., was approved to borrow up to RMB 200 million from its minority shareholder[22] - The company reported a significant increase in short-term borrowings, which rose to ¥3,907,325,697.51 in Q1 2023 from ¥1,381,529,730.87 in Q1 2022[39] Research and Development - Research and development expenses increased to CNY 8.37 million in Q1 2023, up 69.00% from CNY 4.95 million in Q1 2022[33] - The company is collaborating with Nanjing New Industry Investment Group to develop a patient service cloud platform with an estimated R&D cost of CNY 2 million, of which the company will bear CNY 1.2 million[24] - The company is also working on a smart scene support system based on supply chain collaboration, with an estimated R&D cost of CNY 10 million, where the company will cover CNY 6 million[24] - Research and development expenses increased to ¥2,741,509.43 in Q1 2023, up from ¥1,683,541.89 in Q1 2022, reflecting a focus on innovation[41] Shareholder Activities - The company had a total of 65,730 common shareholders at the end of the reporting period[7] - The company repurchased and canceled 84,000 restricted stocks at a price of RMB 2.11 per share due to the departure of four incentive targets[17] - The company completed the sale of 8,456,000 shares from its first employee stock ownership plan[19] - The company reported a cash dividend of CNY 1.40 per 10 shares, totaling CNY 183,444,101.68 for the 2022 fiscal year[25] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[44]

南京医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600713 证券简称：南京医药 编号：ls2023-036 重要内容提示： ● 会议召开时间：2023年5月12日(星期五) 上午 10:00-11:30 ● 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinf o.com/） ● 会议召开方式：上证路演中心网络视频、图文展示及文字互动 ● 投资者可于2023年5月5日(星期五) 至5月11日(星期四)16:00前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司邮箱600713@njyy.com进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 南京医药股份有限公司（以下简称"公司"）已于2023年3月31日发布公司202 2年年度报告，于2023年4月29日发布公司2023年第一季度报告。为便于广大投资者 更全面深入地了解公司2022年度及2023年第一季度的经营成果、 ...

Financial Performance - The company achieved an operating revenue of CNY 50.22 billion in 2022, representing an increase of 11.30% year-on-year[21]. - The net profit attributable to shareholders reached CNY 5.96 billion, up 17.91% compared to the previous year[21]. - Total assets increased by 22.27% year-on-year, amounting to CNY 31.65 billion at the end of 2022[21]. - The net assets attributable to shareholders grew by 30.25% year-on-year, totaling CNY 6.00 billion[21]. - Basic earnings per share decreased by 2.06% to CNY 0.475 in 2022[22]. - The weighted average return on equity was 10.577%, down 0.624 percentage points from the previous year[22]. - The company reported a net cash flow from operating activities of CNY -682.31 million, a significant decline compared to the previous year[21]. - The company achieved a consolidated revenue of CNY 50.222 billion, an increase of 11.30% year-on-year, and a net profit attributable to shareholders of CNY 596 million, up 17.91% year-on-year[64]. Audit and Compliance - The company received a standard unqualified audit report from KPMG Huazhen[4]. - The management has assured the authenticity, accuracy, and completeness of the annual report[8]. - The company has maintained compliance with regulatory requirements regarding the disclosure of financial reports[8]. - The company has not violated decision-making procedures for external guarantees[7]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[7]. - The company has established a management system for insider information, ensuring compliance with regulations and enhancing governance structure[129]. - The internal control audit report issued by KPMG confirmed that the company maintained effective financial reporting internal controls as of December 31, 2022[174]. Risk Management - The company has detailed potential risks in the "Management Discussion and Analysis" section of the report[7]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company has not experienced significant uncollectible accounts receivable, but there is a risk of extended payment terms from public medical institutions due to policy impacts[120]. - The company has committed to preventing insider trading and related party transactions, enhancing its governance level[129]. Strategic Development - The company is focused on strategic development, emphasizing digital empowerment and collaboration in its "14th Five-Year" plan[29]. - The company is enhancing its logistics efficiency through the integration of digital tools and intelligent technologies, aiming for cost reduction and improved collaboration[48]. - The company is committed to building an "Internet + Medicine + Pharmacy + Insurance" ecosystem to enhance service capabilities across all channels and scenarios[50]. - The company aims to become a leading and trusted provider of health products and services in the big health industry, focusing on digitalization and modern supply chain systems[111]. Market and Industry Trends - The pharmaceutical distribution industry in China is undergoing significant transformation due to healthcare reform policies, leading to a slowdown in overall growth and intensified market competition[103]. - The rise of e-pharmacy is reshaping market competition, with online medical consultations and e-commerce rapidly growing, necessitating traditional companies to adapt and integrate online and offline retail[109]. - The retail pharmacy sector is accelerating the upgrade of health services, driven by increasing consumer demand for preventive health and the implementation of new policies like "Internet + Medical Insurance Payment"[106]. Corporate Governance - The company held 11 board meetings and 3 shareholder meetings in 2022, ensuring compliance with governance regulations[125]. - The company has established various committees to enhance governance and oversight[140]. - The company is committed to improving its performance evaluation and compensation management practices for its executives[141]. - The company has implemented a stock incentive plan, resulting in significant shareholding changes for key executives, including an increase of 360,000 shares for the chairman[133]. Social Responsibility - The company actively participated in social responsibility initiatives, including the transportation of pandemic prevention materials to support various regions[36]. - The company invested 806,300 CNY in environmental protection during the reporting period[176]. - The company made a total donation of 1,062,570 CNY for public welfare projects[180]. - The company contributed 2,600 CNY to poverty alleviation and rural revitalization projects, benefiting 4 individuals[181]. Employee and Management Changes - The company reported a significant management change with the departure of several key executives, including the former president Xu Yijie[143]. - The company appointed Zhang Liang as the president and elected him as a director during the shareholders' meeting[142]. - The company has appointed new vice presidents, including Xiao Hong and Peng Yuping, to manage operations[138]. - The new management team is expected to drive future growth and innovation within the company[138]. Investment and Capital Expenditure - Nanjing Pharmaceutical invested CNY 1,530 million to acquire a 51% stake in Bozhou Tianxing Pharmaceutical, with a reported profit of CNY 75.95 million[88]. - The company is investing CNY 17,153 million in the second phase of the Nanjing Pharmaceutical Central Logistics Center, with construction preparations currently underway[94]. - The company approved an investment of up to RMB 41 million for relocating the Chinese medicine decoction service center, with total rental fees not exceeding RMB 31.93 million, including RMB 14.23 million for renovation costs[200].

南京医药股份有限公司 2022 年第三季度报告 证券代码：600713 证券简称：南京医药 南京医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 1 / 15 南京医药股份有限公司 2022 年第三季度报告 一、 主要财务数据 | --- | --- | --- | --- | --- | --- | |------------------------------------------------|-------------------|---------------------------------------|-------------------|---------- ...

南京医药股份有限公司 2022 年半年度报告 公司代码：600713 公司简称：南京医药 南京医药股份有限公司 2022 年半年度报告 1 / 132 南京医药股份有限公司 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人周建军、主管会计工作负责人孙剑及会计机构负责人（会计主管人员）李菁声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司半年度未进行利润分配。 公司2021年度利润分配方案经公司于2022年4月28日召开的2021年年度股东大会审议通过， 以实施权益分派股权登记日登记的总股本1,308,821,012股为基数分配利润，向股权登记日登记在 册的全体股东每10股派发现金红利1.20元(含税) 共计派发现金红利157,058,521.44元（含税）。本 次现金红利发放日为2022年5月27日，现金红利 ...

南京医药股份有限公司 2022 年第一季度报告 证券代码：600713 证券简称：南京医药 南京医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | --- | --- | --- | --- | --- | --- | |----------|-------------------|-------|-------|-------|------------------------| | | | | | | | | | | | | | 本报告期比上年同期增减 | | 项目 | 本报告期 | | | | ...